Dermatology Oncology Strong — AJCC 8th edition / NICE NG14
Breslow Thickness & Melanoma Staging
Breslow thickness is the primary determinant of melanoma T-stage and sentinel lymph node biopsy eligibility. Based on AJCC 8th edition staging.
References
- Gershenwald JE et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017.
- NICE NG14. Melanoma: assessment and management. 2015 (updated 2022).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Grass pollen extracts · Allergen immunotherapy
- House dust mite extracts · Allergen immunotherapy
- Wasp venom extracts · Allergen immunotherapy (venom)
- Bee venom extracts · Allergen immunotherapy (venom)
- Lecanemab (Anti-Amyloid Monoclonal Antibody) · Anti-Amyloid Immunotherapy (IgG1 Monoclonal Antibody)
- Donanemab (Anti-Amyloid Monoclonal Antibody) · Anti-Amyloid Immunotherapy (IgG1 — Targets Pyroglutamate-Modified Amyloid-β)
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.